Trial reportJournal of cardiovascular electrophysiology2026
Self-Administered Etripamil Nasal Spray Slows Ventricular Rate in Patients With Atrial Fibrillation: A Post Hoc Analysis of the NODE-303 Study.
Trial report in Journal of cardiovascular electrophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04072835 (The NODE-303 Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The NODE-303 Study: Multi-Centre, Multi-National,Open Label, Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCurrently, there are no available fast-acting agents to control the ventricular rate (VR) during atrial fibrillation (AF) episodes that can be self-administered by patients on an as-needed basis without medical supervision. Here, we aim to evaluate the effect of intranasal etripamil on VR in patients treating presumed paroxysmal supraventricular tachycardia (PSVT) episodes later identified as AF.
methodsNODE-303 is a phase 3, multicenter, open-label study to evaluate the safety and efficacy of self-administered intranasal etripamil. The study enrolled adult (≥ 18 years) patients with prior documented PSVT. Patients self-administered 70 mg of intranasal etripamil after applying an ECG monitor and performing a vagal maneuver. An optional second 70 mg dose was permitted if symptoms persisted after 10 min. This post hoc analysis specifically focused on AF patients (those with presumed PSVT episodes subsequently identified as AF) and evaluated the change from baseline VR (beats per minute, bpm), calculated using patient ECG data that was recorded through 60 min after drug administration, during an etripamil-treated AF episode.
resultsOf 1116 total enrolled patients, 503 self-administered ≥ 1 dose of etripamil for presumed PSVT, and 18 had ≥ 1 episode(s) later identified as AF with adequate ECG data. AF episode baseline median VR (range) was 127 bpm (79, 164), and the average maximum reduction in VR was 27.4 bpm ± 6.1 at 22 min. VR reduction was sustained for at least 30 to 60 min (median VR reduction -22 and -18 bpm, respectively). No serious adverse events or adverse events of special interest were observed, including bradyarrhythmias, AV block, or sinus pauses ≥ 3 s, and treatment-emergent adverse events were mild to moderate, transient, and related to the nasal administration route. DISCUSSION: In this post hoc subgroup analysis of the open-label NODE-303 trial, self-administered etripamil nasal spray led to a clinically significant and sustained VR reduction in patients with symptomatic AF. Further studies are needed to confirm efficacy in a broader AF population.
conclusionSelf-administered etripamil may help to acutely control symptomatic AF-RVR episodes outside of the healthcare setting. CLINICAL
trial registrationNCT04072835.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.